[Effect of lornoxicam on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome]

Ter Arkh. 2010;82(12):28-32.
[Article in Russian]


Aim: To evaluate the clinical efficacy, safety, and effects of the nonsteroidal anti-inflammatory drug lornoxicam on inflammatory markers in non-ST-segment elevation acute coronary syndrome (NSTEACS).

Subjects and methods: Eighty-five patients with NSTESCS were enrolled in a prospective randomized study. They were divided into 2 groups: 1) patients received lornoxicam (8 or 12 mg/daily) for 15 days in addition to standard treatment and 2) controls. Cardiovascular outcomes and the levels of C-reactive protein (CRP), IL-6, and IL-10 were determined.

Results: The lornoxicam group exhibited a significant reduction in CRP and a decrease in IL-6. There was also a significant increase in IL-10 levels in this group. A 6-month follow-up indicated a significant reduction in the number of cardiovascular events (nonfatal myocardial infarction, unstable angina, coronary death).

Conclusion: Lornoxicam reduces the risk of poor cardiovascular outcomes in patients with NSTEACS and the levels of inflammatory markers.

Publication types

  • Comparative Study
  • English Abstract
  • Randomized Controlled Trial

MeSH terms

  • Acute Coronary Syndrome / blood
  • Acute Coronary Syndrome / drug therapy*
  • Acute Coronary Syndrome / physiopathology
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Biomarkers / blood*
  • C-Reactive Protein / drug effects
  • C-Reactive Protein / metabolism
  • Dose-Response Relationship, Drug
  • Electrocardiography*
  • Female
  • Follow-Up Studies
  • Humans
  • Interleukin-10 / blood
  • Interleukin-6 / blood
  • Male
  • Piroxicam / administration & dosage
  • Piroxicam / analogs & derivatives*
  • Piroxicam / therapeutic use
  • Prospective Studies
  • Treatment Outcome


  • Anti-Inflammatory Agents, Non-Steroidal
  • Biomarkers
  • Interleukin-6
  • Interleukin-10
  • Piroxicam
  • C-Reactive Protein
  • lornoxicam